Clinical Trials Logo

TOR Serine-Threonine Kinases clinical trials

View clinical trials related to TOR Serine-Threonine Kinases.

Filter by:
  • None
  • Page 1

NCT ID: NCT01960829 Recruiting - Melanoma Clinical Trials

Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety. The study objective is to evaluate efficacy profile of everolimus. The patients who comply with the inclusion and exclusion criteria will be enrolled. The estimated recruiting duration is 18 months. Everolimus will be given in the dose of 10 mg orally each day at lease 6 months unless disease progression or intolerance. The follow-up is till death(at least 1 year).